Acquired resistance of leukemic cells to AraC is associated with the upregulation of aldehyde dehydrogenase 1 family member A2

Experimental Hematology

Volumn 41, Issue 7, 2013, Pages 597-603.e2

  Kawasoe, Misaki ^a   Yamamoto, Yasuko ^a   Okawa, Katsuya ^b   Funato, Tadao ^c   Takeda, Mayu ^c   Hara, Takeshi ^d   Tsurumi, Hisashi ^d   Moriwaki, Hisataka ^d   Arioka, Yuko ^a   Takemura, Masao ^a   Matsunami, Hidetoshi ^e   Markey, Sanford P ^f   Saito, Kuniaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c TOHOKU FUKUSHI UNIVERSITY   (Japan)

^d GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Matsunami General Hospital   (Japan)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBER A2; CYTARABINE; IDARUBICIN; UNCLASSIFIED DRUG; VIMENTIN;

ALDH1A2 GENE; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; GEL ELECTROPHORESIS; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84879605537     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.03.004     Document Type: Article

References (25)

1. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43.
2. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
3. Cunningham I. A basis for updating our approach to resistant acute leukemia. Am J Hematol 2012, 87:251-257.
4. Braess J., Freund M., Hanauske A., et al. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma-phase I/II studies and pharmacokinetics. Leukemia 1998, 12:1618-1626.
5. Flasshove M., Strumberg D., Ayscue L., et al. Structural-analysis of the deoxycytidine kinase gene in patients with acute myeloid-leukemia and resistance to cytosine-arabinoside. Leukemia 1994, 8:780-785.
6. Abdel-Aziz W., Jiang H.Y., Hickey R.J., Malkas L.H. Ara-C affects formation of cancer cell DNA synthesome replication intermediates. Cancer Chemother Pharmacol 2000, 45:312-319.
7. Abraham A., Varatharajan S., Abbas S., et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 2012, 13:269-282.
8. Laliberte J., Momparler R.L. Human cytidine deaminase - purification of enzyme, cloning, and expression of its complementary-DNA. Cancer Res 1994, 54:5401-5407.
9. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
10. Popkov M., Lussier I., Medvedkine V., et al. Multidrug-resistance drug-binding peptides generated by using a phage display library. Eur J Biochem 1998, 251:155-163.
11. White J.C., Hines L.H., Winters K.L. Concentration-dependence of cytosine-arabinoside (Ara-C) phosphorylation by human-leukemia cells and human Ara-C kinase. Proc Am Assoc Cancer Res 1987, 28. 323.
12. Jin G., Matsushita H., Asai S., et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Comm 2009, 390:1001-1006.
13. Funato T., Satou J., Nishiyama Y., et al. Invitro leukemia cell models of Ara-C resistance. Leuk Res 2000, 24:535-541.
14. Zhou G., Li H.M., DeCamp D., et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
15. Jensen O.N., Podtelejnikov A., Mann M. Delayed extraction improves specificity in database searches by matrix-assisted laser desorption/ionization peptide maps. Rapid Comm Mass Spectrom 1996, 10:1371-1378.
16. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
17. Moreb J.S., Ucar D., Han S., et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by dimethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 2012, 195:52-60.
18. Pappa A., Brown D., Koutalos Y., et al. Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem 2005, 280:27998-28006.
19. Muzio G., Maggiora M., Paiuzzi E., Oraldi M., Canuto R.A. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 2012, 52:735-746.
20. Yoon W.H., Song I.S., Lee B.H., et al. Differential regulation of vimentin mRNA by 12-O-tetradecanoylphorbol 13-acetate and all-trans-retinoic acid correlates with motility of Hep 3B human hepatocellular carcinoma cells. Cancer Lett 2004, 203:99-105.
21. Yoshida A., Rzhetsky A., Hsu L.C., Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998, 251:549-557.
22. Sreerama L., Sladek N.E. Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clin Cancer Res 1997, 3:1901-1914.
23. De Luca L.M. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991, 5:2924-2933.
24. Kitamura M., Ishikawa Y., Moreno-Manzano V., et al. Intervention by retinoic acid in oxidative stress-induced apoptosis. Nephrol Dial Transplant 2002, 17:84-87.
25. Moreno-Manzano V., Ishikawa Y., Lucio-Cazana J., Kitamura M. Suppression of apoptosis by all-trans-retinoic acid. Dual intervention in the c-Jun N-terminal kinase-AP-1 pathway. J Biol Chem 1999, 274:20251-20258.